In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...
Even so, this relatively lean state had among the nation’s biggest surges last year in residents taking blockbuster weight-loss drugs ... such as Wegovy and Zepbound in 2024, a 255 percent ...
Weight loss was still increasing at Week 36, implying Kailera and Hengrui Pharma can go past 22.8%. The data suggest HRS9531 has similar efficacy to Eli Lilly’s Zepbound. Lilly won approval for ...
7don MSN
While weight-loss drugs were linked to lower risk of some conditions, they were also associated with some adverse health ...
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback